EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY 4.0

Guidance for Administering Biologics for Severe Asthma and Allergic Conditions

Delbert R Dorscheid iD, Jason K Lee iD, Warren Ramesh iD, Mark Greenwald iD, Jaime Del Carpio iD

Canadian Respiratory Journal · 10.09.2022 · 2022 · 1-9

DOI: 10.1155/2022/9355606 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Canadian Respiratory Journal, erschienen am 10.09.2022. Verfasst von Delbert R Dorscheid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory and Critical Care Medicine, St. Paul's Hospital, Center for Heart Lung Innovation, University of British Columbia, Vancouver,…. Hauptthemen laut MEDLINE: Asthma, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xcenda.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a common respiratory disorder in Canada for which biologics may be prescribed for poorly controlled illness. Treatment with biologics, however, is sometimes inappropriately discontinued due to misconceptions regarding their potential immunologic effects, and concerns surrounding their continued use in severe asthma during the COVID-19 pandemic continue to propagate. Biologics can still be administered in a majority of health and treatment conditions. With regard to cardiac-related issues such as hypertension or cardiovascular disease (CVD), there is no solid evidence that suggests biologics should be withheld, as the benefits of treatment outweigh the risks. Asthmatic patients on biologic treatment should also continue treatment if they have, or are currently being treated for, a respiratory infection, including COVID-19. Evidence also indicates the importance of maintaining asthma control to reduce the risk of severe COVID-19 infection. Biologic treatment can be administered in severe asthmatic patients with bronchiectasis, though further evidence is needed to better understand the benefits. Biologic treatment should be continued postsurgery to reduce postoperative respiratory complications, as well as throughout the course of pregnancy. Regarding concerns over vaccine administration, nearly all vaccines can be given without interruption of biologic treatment in patients with severe asthma or allergic conditions. Appropriate screening for respiratory illnesses, such as COVID-19, continues to be warranted in clinical practices to reduce the risk of transmission. As recommendations from public health and regulatory agencies have been lacking, this guidance document addresses the administration of biologics in different health circumstances and respiratory illness screening during the COVID-19 pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsFemaleHumansPregnancyCOVID-19PandemicsPublic HealthMale

Substanzen

Biological Products

Autor:innen und Institutionen

  • Division of Respiratory and Critical Care Medicine, St. Paul's Hospital, Center for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia V6Z 1Y6, Canada.
  • Clinical Immunology & Allergy Internal Medicine, Evidence Based Medical Educator Inc. & Urticaria Canada, Biologics and Therapeutics Committee, ACAAI, Toronto M5G 1E2 ON, Canada.
  • Royal Alexandra Hospital, Edmonton Respiratory Consultants, Edmonton, Alberta T5J 3S9, Canada.
  • University of Toronto and Queen's University, Toronto, Ontario M5S 1A1, Canada.
  • Division of Allergy and Clinical Immunology, McGill University, Montreal H3A 0G4, Quebec, Canada.

ORCID-Profile: Delbert R Dorscheid, Jason K Lee, Warren Ramesh, Mark Greenwald, Jaime Del Carpio

Förderung

  • Xcenda

Zitieren

APA

Dorscheid, D. R., Lee, J. K., Ramesh, W., Greenwald, M., & Del Carpio, J. (2022). Guidance for Administering Biologics for Severe Asthma and Allergic Conditions. Canadian Respiratory Journal, 2022, 1-9. https://doi.org/10.1155/2022/9355606

Vancouver

Dorscheid DR, Lee JK, Ramesh W, Greenwald M, Del Carpio J. Guidance for Administering Biologics for Severe Asthma and Allergic Conditions. Canadian Respiratory Journal. 2022;2022:1-9. doi:10.1155/2022/9355606

BibTeX
@article{Dorscheid2022,
  author = {Dorscheid, Delbert R and Lee, Jason K and Ramesh, Warren and Greenwald, Mark and Del Carpio, Jaime},
  title = {Guidance for Administering Biologics for Severe Asthma and Allergic Conditions},
  journal = {Canadian Respiratory Journal},
  year = {2022},
  volume = {2022},
  pages = {1--9},
  doi = {10.1155/2022/9355606}
}
Kostenlos starten →